In a Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s DrugThe agency faced criticism for approving Aduhelm for all Alzheimer’s patients. The new label recommends that the drug be given only to patients with mild symptoms.In a Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drug
'Some Hope Is Better Than Having No Hope' · The New York Times'Some Hope Is Better Than Having No Hope' · The New York Times
Controversial Alzheimer’s drug could cost US $334B—nearly half of DoD budgetDespite unproven efficacy, Biogen set the drug’s list price at $56,000 per year.Controversial Alzheimer’s drug could cost US $334B—nearly half of DoD budget
New Drug Could Cost the Government as Much as It Spends on NASAThe Alzheimer’s treatment will cost $56,000 per patient, and millions may use it. The result: “crazy numbers” for Medicare.New Drug Could Cost the Government as Much as It Spends on NASA
Hospital consolidation influences physicians’ practice patterns: ResearchWhen hospitals acquire physician practices, it can influence how individual physicians practice medicine, two new studies show.Hospital consolidation influences physicians’ practice patterns: Research
The new Alzheimer’s drug that could break MedicarePatients are desperate for hope. But there are serious concerns about Biogen’s new $56,000 treatment.The new Alzheimer’s drug that could break Medicare